{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:29:43Z","timestamp":1787020183383,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A 3-year single-centre, retrospective, comparative, non-randomized cohort study to describe the long-term outcomes of treatment-na\u00efve, Caucasian and non-Caucasian eyes with polypoidal choroidal vasculopathy (PCV) after treatment with predominantly Bevacizumab monotherapy or in combination with rescue photodynamic therapy (PDT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Demographics, visual outcomes, optical coherence tomography (OCT) and treatment data were collected up to 3\u2009years after the first visit. Stratified analysis according to ethnicity and baseline vision was performed to identify factors predictive of long-term visual improvement and maintenance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 89 eyes with PCV were identified, of which 14 received rescue verteporfin PDT. There was an equal distribution between Caucasian and non-Caucasian individuals. Non-Caucasians present at a younger age (67.3 vs. 76.0\u2009years,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.002), have a higher proportion of foveal involvement (80.9%, vs.54.2%\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.007), choroidal hyperpermeability (50% vs 25.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.013) and lower baseline visual acuity (53.1 vs. 63.3 letters,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.008). Mean visual acuity (VA) gain was +\u20098.9 letters and\u2009+\u20095.0 letters at 1 and 3 years of follow-up, respectively. Non-Caucasian individuals had a lower mean final visual acuity (VA) (54.7 vs. 70.5, respectively;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u20090.001) and net gain in VA (+\u20092.0 vs.\u2009+\u20097.6 letters,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.581) compared to Caucasian individuals. The mean total number of injections given over 3 years was 14.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Most patients treated with predominantly Bevacizumab anti-vascular endothelial growth factor (VEGF) monotherapy achieved sustained visual acuity gains out to 3\u2009years. Due to ethnic-specific differences in presenting PCV phenotypes, non-Caucasians presented with lower baseline VA and had poorer long-term visual outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-022-02551-3","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T04:02:48Z","timestamp":1658980968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ethnic differences on long term outcomes of polypoidal choroidal vasculopathy after predominantly bevacizumab monotherapy"],"prefix":"10.1186","volume":"22","author":[{"given":"Aaron","family":"Yap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Squirrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"2551_CR1","first-page":"1","volume":"32","author":"LA Yannuzzi","year":"2012","unstructured":"Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina (Philadelphia, Pa). 2012;32:1\u20138.","journal-title":"Retina (Philadelphia, Pa)."},{"issue":"2","key":"2551_CR2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/ceo.13114","volume":"46","author":"KK Dansingani","year":"2018","unstructured":"Dansingani KK, Gal-Or O, Sadda SR, Yannuzzi LA, Freund KB. Understanding aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy): a lesson in the taxonomy of \u2018expanded spectra\u2019 - a review. Clin Exp Ophthalmol. 2018;46(2):189\u2013200.","journal-title":"Clin Exp Ophthalmol"},{"issue":"11","key":"2551_CR3","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","volume":"135","author":"A Koh","year":"2017","unstructured":"Koh A, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, et al. Efficacy and safety of Ranibizumab with or without Verteporfin photodynamic therapy for Polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol. 2017;135(11):1206\u201313.","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"2551_CR4","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","volume":"136","author":"WK Lee","year":"2018","unstructured":"Lee WK, Iida T, Ogura Y, Chen S-J, Wong TY, Mitchell P, et al. Efficacy and safety of intravitreal Aflibercept for Polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol. 2018;136(7):786\u201393.","journal-title":"JAMA Ophthalmol"},{"key":"2551_CR5","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ajo.2021.08.006","volume":"234","author":"F Corvi","year":"2022","unstructured":"Corvi F, Chandra S, Invernizzi A, Pace L, Viola F, Sivaprasad S, et al. Multimodal imaging comparison of Polypoidal choroidal vasculopathy between Asian and Caucasian populations. Am J Ophthalmol. 2022;234:108\u201316.","journal-title":"Am J Ophthalmol"},{"key":"2551_CR6","volume-title":"Auckland Region Census Place Summaries","author":"Stats NZ","year":"2018","unstructured":"Stats NZ. Auckland Region Census Place Summaries 2018."},{"issue":"3","key":"2551_CR7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","volume":"128","author":"CMG Cheung","year":"2021","unstructured":"Cheung CMG, Lai TYY, Teo K, Ruamviboonsuk P, Chen SJ, Kim JE, et al. Polypoidal choroidal vasculopathy: consensus nomenclature and non-Indocyanine green angiograph diagnostic criteria from the Asia-Pacific ocular imaging society PCV workgroup. Ophthalmology. 2021;128(3):443\u201352.","journal-title":"Ophthalmology."},{"issue":"1","key":"2551_CR8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/IAE.0b013e318296b271","volume":"34","author":"MC Gillies","year":"2014","unstructured":"Gillies MC, Walton R, Liong J, Arnold JJ, McAllister I, Morlet N, et al. Efficient capture of high-quality data on outcomes of treatment for macular diseases: the fight retinal blindness! Project. Retina (Philadelphia, Pa). 2014;34(1):188\u201395.","journal-title":"Retina (Philadelphia, Pa)."},{"issue":"4","key":"2551_CR9","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ajo.2006.05.051","volume":"142","author":"M Sasahara","year":"2006","unstructured":"Sasahara M, Tsujikawa A, Musashi K, Gotoh N, Otani A, Mandai M, et al. Polypoidal choroidal vasculopathy with choroidal vascular hyperpermeability. Am J Ophthalmol. 2006;142(4):601\u20137 e1.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"2551_CR10","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ajo.2015.08.028","volume":"160","author":"KK Dansingani","year":"2015","unstructured":"Dansingani KK, Balaratnasingam C, Klufas MA, Sarraf D, Freund KB. Optical coherence tomography angiography of shallow irregular pigment epithelial detachments in pachychoroid spectrum disease. Am J Ophthalmol. 2015;160(6):1243\u201354 e2.","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"2551_CR11","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.oret.2019.06.013","volume":"3","author":"M Hata","year":"2019","unstructured":"Hata M, Tagawa M, Oishi A, Kawashima Y, Nakata I, Akagi-Kurashige Y, et al. Efficacy of photodynamic therapy for polypoidal choroidal vasculopathy associated with and without pachychoroid phenotypes. Ophthalmology Retina. 2019;3(12):1016\u201325.","journal-title":"Ophthalmology Retina"},{"key":"2551_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0000000000000774","volume":"36","author":"C Balaratnasingam","year":"2016","unstructured":"Balaratnasingam C, Lee W-K, Koizumi H, Dansingani K, Inoue M, Freund KB. Polypoidal choroidal vasculopathy: a distinct disease or manifestation of many? Retina. 2016;36:1\u20138 LWW.","journal-title":"Retina"},{"issue":"2","key":"2551_CR13","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ajo.2014.04.021","volume":"158","author":"CE Pang","year":"2014","unstructured":"Pang CE, Shah VP, Sarraf D, Freund KB. Ultra-Widefield imaging with autofluorescence and Indocyanine green angiography in central serous Chorioretinopathy. Am J Ophthalmol. 2014;158(2):362\u201371.e2.","journal-title":"Am J Ophthalmol"},{"key":"2551_CR14","volume-title":"Ethnicity New Zealand Standard Classification","author":"NZ Stats","year":"2005","unstructured":"Stats NZ. Ethnicity New Zealand Standard Classification; 2005."},{"issue":"11","key":"2551_CR15","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.ophtha.2010.02.032","volume":"117","author":"OP Gupta","year":"2010","unstructured":"Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration: clinical and economic impact. Ophthalmology. 2010;117(11):2134\u201340.","journal-title":"Ophthalmology."},{"issue":"1","key":"2551_CR16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ophtha.2015.09.018","volume":"123","author":"K Berg","year":"2016","unstructured":"Berg K, Hadzalic E, Gjertsen I, Forsaa V, Berger LH, Kinge B, et al. Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the lucentis compared to avastin study treat-and-extend protocol: two-year results. Ophthalmology. 2016;123(1):51\u20139.","journal-title":"Ophthalmology."},{"issue":"7","key":"2551_CR17","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/bjophthalmol-2015-306987","volume":"100","author":"D Chin-Yee","year":"2016","unstructured":"Chin-Yee D, Eck T, Fowler S, Hardi A, Apte RS. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol. 2016;100(7):914\u20137.","journal-title":"Br J Ophthalmol"},{"key":"2551_CR18","volume-title":"Decision to fund aflibercept and rivaroxaban","author":"PHARMAC","year":"2018","unstructured":"PHARMAC. Decision to fund aflibercept and rivaroxaban 2018 [Available from: https:\/\/pharmac.govt.nz\/news-and-resources\/consultations-and-decisions\/decision-to-fund-aflibercept-and-rivaroxaban\/#aflibercept."},{"issue":"4","key":"2551_CR19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1089\/jop.2015.0073","volume":"32","author":"YS Chang","year":"2016","unstructured":"Chang YS, Kim JH, Kim KM, Kim JW, Lee TG, Kim CG, et al. Long-term outcomes of anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy. J Ocul Pharmacol Ther. 2016;32(4):219\u201324.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"2551_CR20","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1111\/aos.13461","volume":"96","author":"SS Gharehbagh","year":"2018","unstructured":"Gharehbagh SS, Subhi Y, S\u00f8rensen TL. Efficacy of aflibercept for polypoidal choroidal vasculopathy in Caucasians. Acta Ophthalmol. 2018;96(1):e94\u2013e5.","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"2551_CR21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/bjophthalmol-2017-310448","volume":"102","author":"T Hikichi","year":"2018","unstructured":"Hikichi T. Six-year outcomes of antivascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2018;102(1):97\u2013101.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"2551_CR22","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ajo.2012.09.020","volume":"155","author":"HM Kang","year":"2013","unstructured":"Kang HM, Kim YM, Koh HJ. Five-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013;155(3):438\u201347 e1.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"2551_CR23","doi-asserted-by":"crossref","first-page":"e0229231","DOI":"10.1371\/journal.pone.0229231","volume":"15","author":"K Wataru","year":"2020","unstructured":"Wataru K, Sugiyama A, Yoneyama S, Matsubara M, Fukuda Y, Parikh R, et al. Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy. PLoS One. 2020;15(2):e0229231.","journal-title":"PLoS One"},{"issue":"4","key":"2551_CR24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.oret.2019.10.019","volume":"4","author":"BJ Fenner","year":"2020","unstructured":"Fenner BJ, Ting DSW, Tan ACS, Teo K, Chan CM, Mathur R, et al. Real-world treatment outcomes of age-related macular degeneration and Polypoidal choroidal vasculopathy in Asians. Ophthalmol Retina. 2020;4(4):403\u201314.","journal-title":"Ophthalmol Retina"},{"issue":"4","key":"2551_CR25","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/IAE.0b013e3182852446","volume":"33","author":"AH Koh","year":"2013","unstructured":"Koh AH, Chen L-J, Chen S-J, Chen Y, Giridhar A, Iida T, et al. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina (Philadelphia, Pa). 2013;33(4):686\u2013716.","journal-title":"Retina (Philadelphia, Pa)."},{"key":"2551_CR26","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1136\/bjophthalmol-2020-318354","volume":"106","author":"KYC Teo","year":"2022","unstructured":"Teo KYC, Jordan-Yu JM, Tan AC, Yeo IY, Mathur R, Chan CM, et al. Efficacy of a novel personalised aflibercept monotherapy regimen based on polypoidal lesion closure in participants with polypoidal choroidal vasculopathy. Br J Ophthalmol. 2022;106:987\u201393.","journal-title":"Br J Ophthalmol."},{"key":"2551_CR27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2019.10.007","volume":"210","author":"M Gillies","year":"2020","unstructured":"Gillies M, Arnold J, Bhandari S, Essex RW, Young S, Squirrell D, et al. Ten-year treatment outcomes of Neovascular age-related macular degeneration from two regions. Am J Ophthalmol. 2020;210:116\u201324.","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"2551_CR28","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","volume":"122","author":"MC Gillies","year":"2015","unstructured":"Gillies MC, Campain A, Barthelmes D, Simpson JM, Arnold JJ, Guymer RH, et al. Long-term outcomes of treatment of Neovascular age-related macular degeneration: data from an observational study. Ophthalmology. 2015;122(9):1837\u201345.","journal-title":"Ophthalmology."},{"issue":"5","key":"2551_CR29","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.survophthal.2019.02.008","volume":"64","author":"J Talks","year":"2019","unstructured":"Talks J, Daien V, Finger RP, Eldem B, Sakamoto T, Cardillo JA, et al. The use of real-world evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration. Surv Ophthalmol. 2019;64(5):707\u201319.","journal-title":"Surv Ophthalmol"},{"issue":"11","key":"2551_CR30","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(11):2292\u20139.","journal-title":"Ophthalmology."},{"issue":"1","key":"2551_CR31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10384-007-0498-2","volume":"52","author":"SH Byeon","year":"2008","unstructured":"Byeon SH, Lee SC, Oh H-S, Kim SS, Koh HJ, Kwon OW. Incidence and clinical patterns of polypoidal choroidal vasculopathy in Korean patients. Jpn J Ophthalmol. 2008;52(1):57\u201362.","journal-title":"Jpn J Ophthalmol"},{"issue":"10","key":"2551_CR32","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1001\/archopht.121.10.1392","volume":"121","author":"K Sho","year":"2003","unstructured":"Sho K, Takahashi K, Yamada H, Wada M, Nagai Y, Otsuji T, et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol (Chicago, Ill : 1960). 2003;121(10):1392\u20136.","journal-title":"Arch Ophthalmol (Chicago, Ill : 1960)"},{"key":"2551_CR33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.preteyeres.2016.04.002","volume":"53","author":"CW Wong","year":"2016","unstructured":"Wong CW, Yanagi Y, Lee W-K, Ogura Y, Yeo I, Wong TY, et al. Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res. 2016;53:107\u201339.","journal-title":"Prog Retin Eye Res"},{"issue":"5","key":"2551_CR34","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/sj.eye.6700706","volume":"18","author":"ID Ladas","year":"2004","unstructured":"Ladas ID, Rouvas AA, Moschos MM, Synodinos EE, Karagiannis DA, Koutsandrea CN. Polypoidal choroidal vasculopathy and exudative age-related macular degeneration in Greek population. Eye (Lond). 2004;18(5):455\u20139.","journal-title":"Eye (Lond)"},{"issue":"9","key":"2551_CR35","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s004170000180","volume":"238","author":"B Lafaut","year":"2000","unstructured":"Lafaut B, Leys A, Snyers B, Rasquin F, De Laey JJ. Polypoidal choroidal vasculopathy in Caucasians. Graefes Arch Clin Exp Ophthalmol. 2000;238(9):752\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"2551_CR36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00006982-200104000-00004","volume":"21","author":"B Scassellati-Sforzolini","year":"2001","unstructured":"Scassellati-Sforzolini B, Mariotti C, Bryan R, Yannuzzi LA, Giuliani M, Giovannini A. Polypoidal choroidal vasculopathy in Italy. Retina (Philadelphia, Pa). 2001;21(2):121\u20135.","journal-title":"Retina (Philadelphia, Pa)"},{"issue":"11","key":"2551_CR37","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1001\/archopht.117.11.1503","volume":"117","author":"LA Yannuzzi","year":"1999","unstructured":"Yannuzzi LA, Wong DW, Sforzolini BS, Goldbaum M, Tang KC, Spaide RF, et al. Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Arch Ophthalmol. 1999;117(11):1503\u201310.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"2551_CR38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00417-020-04844-z","volume":"259","author":"EHC van Dijk","year":"2021","unstructured":"van Dijk EHC, Mohabati D, Veselinovic S, Chung WH, Dijkman G, Boon CJF. The spectrum of polypoidal choroidal vasculopathy in Caucasians: clinical characteristics and proposal of a classification. Graefes Arch Clin Exp Ophthalmol. 2021;259(2):351\u201361.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"2551_CR39","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.survophthal.2010.03.004","volume":"55","author":"Y Imamura","year":"2010","unstructured":"Imamura Y, Engelbert M, Iida T, Freund KB, Yannuzzi LA. Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol. 2010;55(6):501\u201315.","journal-title":"Surv Ophthalmol"},{"issue":"8","key":"2551_CR40","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/bjo.86.8.892","volume":"86","author":"AK Kwok","year":"2002","unstructured":"Kwok AK, Lai TY, Chan CW, Neoh EL, Lam DS. Polypoidal choroidal vasculopathy in Chinese patients. Br J Ophthalmol. 2002;86(8):892\u20137.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"2551_CR41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","volume":"144","author":"I Maruko","year":"2007","unstructured":"Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007;144(1):15\u201322.","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"2551_CR42","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/archopht.117.8.1035","volume":"117","author":"M Uyama","year":"1999","unstructured":"Uyama M, Matsubara T, Fukushima I, Matsunaga H, Iwashita K, Nagai Y, et al. Idiopathic polypoidal choroidal vasculopathy in Japanese patients. Arch Ophthalmol. 1999;117(8):1035\u201342.","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"2551_CR43","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00417-003-0667-z","volume":"242","author":"F Wen","year":"2004","unstructured":"Wen F, Chen C, Wu D, Li H. Polypoidal choroidal vasculopathy in elderly Chinese patients. Graefes Arch Clin Exp Ophthalmol. 2004;242(8):625\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"2551_CR44","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1167\/iovs.14-16236","volume":"56","author":"G Coscas","year":"2015","unstructured":"Coscas G, Lupidi M, Coscas F, Benjelloun F, Zerbib J, Dirani A, et al. Toward a specific classification of polypoidal choroidal vasculopathy: idiopathic disease or subtype of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2015;56(5):3187\u201395.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"2551_CR45","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/bjophthalmol-2013-303444","volume":"98","author":"K Hatz","year":"2014","unstructured":"Hatz K, Pr\u00fcnte C. Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response. Br J Ophthalmol. 2014;98(2):188\u201394.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"2551_CR46","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0002-9394(02)01404-6","volume":"133","author":"M Uyama","year":"2002","unstructured":"Uyama M, Wada M, Nagai Y, Matsubara T, Matsunaga H, Fukushima I, et al. Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol. 2002;133(5):639\u201348.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"2551_CR47","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/bjo.84.5.479","volume":"84","author":"RM Ahuja","year":"2000","unstructured":"Ahuja RM, Stanga PE, Vingerling JR, Reck AC, Bird AC. Polypoidal choroidal vasculopathy in exudative and haemorrhagic pigment epithelial detachments. Br J Ophthalmol. 2000;84(5):479\u201384.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"2551_CR48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1756-185X.12126","volume":"17","author":"V Milne","year":"2014","unstructured":"Milne V, Kearns R, Harrison A. Patient age, ethnicity and waiting times determine the likelihood of non-attendance at a first specialist rheumatology assessment. Int J Rheum Dis. 2014;17(1):19\u201325.","journal-title":"Int J Rheum Dis"},{"issue":"7","key":"2551_CR49","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/ceo.13528","volume":"47","author":"J Ramke","year":"2019","unstructured":"Ramke J, Jordan V, Vincent AL, Harwood M, Murphy R, Ameratunga S. Diabetic eye disease and screening attendance by ethnicity in New Zealand: a systematic review. Clin Exp Ophthalmol. 2019;47(7):937\u201347.","journal-title":"Clin Exp Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02551-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-022-02551-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02551-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T11:01:01Z","timestamp":1659092461000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-022-02551-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2551"],"URL":"https:\/\/doi.org\/10.1186\/s12886-022-02551-3","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"assertion":[{"value":"1 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocols were approved by the Auckland District Health Board Research Review committee, approval number A\u2009+\u20099628. This study was conducted in accordance with the tenets of the Declaration of Helsinki. The Auckland District Health Board Research Review committee waived the requirements for informed consent because of the retrospective nature of the study and use of anonymized retinal images and clinical data. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"325"}}